Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

430

Employees430

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

430

Employees430

ARVN Key Statistics

Market cap

698.57M

Market cap698.57M

Price-Earnings ratio

-1.84

Price-Earnings ratio-1.84

Dividend yield

—

Dividend yield—

Average volume

2.65M

Average volume2.65M

High today

$9.70

High today$9.70

Low today

$9.21

Low today$9.21

Open price

$9.46

Open price$9.46

Volume

1.95M

Volume1.95M

52 Week high

$29.61

52 Week high$29.61

52 Week low

$5.90

52 Week low$5.90

ARVN News

TipRanks 4d

Arvinas downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs downgraded Arvinas (ARVN) to Sell from Neutral with a price target of $6, down from $8. The firm says the “rapidly evolving” competitive landscape...

Analyst ratings

50%

of 18 ratings

Buy

44.4%

Hold

50%

Sell

5.6%

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.